Advancing CML and Leukemia Care with TKIs, CAR-T, and AI

In this episode of MD Newsline, Dr. Elias Jabbour, Professor of Medicine at MD Anderson Cancer Center, shares groundbreaking insights into the evolving treatment landscape of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). He discusses the transformative role of tyrosine kinase inhibitors (TKIs), strategies to achieve treatment-free remission, and how genetic testing, CAR-T therapy, and monoclonal antibodies are reshaping frontline and relapsed leukemia management. Episode Highlights: The TKI Revolution in CML Dr. Jabbour recounts how TKIs have shifted CML from a fatal disease to one with normal life expectancy, even allowing for treatment discontinuation in select patients after prolonged deep molecular remission. He explains how monitoring and response milestones guide therapy and when mutation testing is necessary. Understanding Resistance and Personalized Care Resistance to TKIs is rare when patients are compliant. Dr. Jabbour outlines how NGS is used to detect kinase domain mutations and guide next-line therapy, particularly in BCR-ABL-independent resistance. He also shares why genomic profiling isn't yet used for frontline CML treatment but may become more relevant in advanced disease. Integrating Immunotherapy in ALL In adult ALL, Dr. Jabbour explains how immunotherapy and TKIs are reducing the need for chemotherapy and transplantation, improving both survival and quality of life. He discusses how CAR-T therapy may move to the frontline setting to shorten treatment duration and potentially eliminate the need for allogeneic transplant. AML: Moving Toward Targeted Frontline Therapy Dr. Jabbour outlines how FLT3, IDH, and menin inhibitors are improving outcomes in AML, especially when combined with hypomethylating agents and venetoclax. He stresses the importance of minimal residual disease (MRD) monitoring to tailor therapy and reduce overtreatment. Overcoming Barriers and Promoting Access He reflects on challenges like drug cost, limited access to specialized care, and clinical trial barriers such as travel and housing. Dr. Jabbour calls for simplified regimens that can be delivered anywhere, so that all patients—not just those at top centers—can benefit from the latest innovations. Key Takeaway: With the right combinations of targeted therapies, immunotherapies, and patient-specific monitoring, many leukemias—especially CML and ALL—are becoming manageable or even curable. But equitable access, affordability, and ongoing collaboration are essential to truly transform care worldwide. Resources: Website: https://mdnewsline.com Newsletter: https://mdnewsline.com/subscribe Connect with Dr. Elias Jabbour: MD Anderson Profile Hosted on Acast. See acast.com/privacy for more information.